After the Tick Bite: What Clinicians Need to Know

By Dr. Myriah Hinchey, ND, FMAPS, FILADS, Medical Director, TAO Vitality | Founder, LymeCore Botanicals Summary: The acute window following a tick bite is the highest-yield period for early detection and also the period when standard diagnostic approaches are least reliable. A sound tick bite testing protocol for this window must account for the biological… Continue reading After the Tick Bite: What Clinicians Need to Know

Bay Area Lyme Ventures Invests in Galaxy Diagnostics to Advance Tick-Borne Disease Testing

Bay Area Lyme Ventures invests in Galaxy Diagnostics to advance innovation in tick-borne disease diagnostics.

Partnership Aims to Accelerate Innovation in Diagnostic Tools for Patients with Complex Tick and Vector-Borne Illnesses DURHAM, N.C., June 2nd, 2026, Galaxy Diagnostics, a leader in advanced vector-borne disease testing, has announced a strategic investment from Bay Area Lyme Ventures, the newly launched impact investment fund created by Bay Area Lyme Foundation to accelerate innovation… Continue reading Bay Area Lyme Ventures Invests in Galaxy Diagnostics to Advance Tick-Borne Disease Testing

The Babesia Detection Problem: Why Results Differ in Low-Level Parasitemia

By Jennifer C. Miller, PhD, Vice President of Clinical & Scientific Operations, Galaxy Diagnostics   Summary: Babesia is an intraerythrocytic parasite that has become one of the most persistent diagnostic blind spots in tick-borne medicine. Despite growing clinical recognition, standard testing methods frequently fail to detect Babesia in chronic presentations, where parasitemia is low, symptoms… Continue reading The Babesia Detection Problem: Why Results Differ in Low-Level Parasitemia

REPLAY: The Black Box of Vector-Borne Pathogens

Babesia is often present but rarely detected. In this clinical webinar, learn why standard diagnostics fall short, how pathogen biology creates testing gaps, and how to interpret discordant results with confidence.

REPLAY: Bartonella: The Blind Spot Pathogen

When Bartonella infections persist, present atypically, or defy standard testing, understanding why they are missed is critical. This webinar examines Bartonella’s stealth biology, non-traditional transmission routes, and diagnostic blind spots through clinically grounded case studies, providing actionable insight for providers navigating complex vector-borne disease presentations.

Bartonella: The Blind Spot Pathogen Clinicians Can’t Afford to Miss

Galaxy Diagnostics discusses why the blindspot pathogen Bartonella diagnosis missed

By Edward B. Breitschwerdt, DVM, Co-Founder, Galaxy Diagnostics, and Distinguished Professor Emeritus of Internal Medicine and Infectious Diseases, NC State University College of Veterinary Medicine   Summary: Bartonella is one of the most diagnostically overlooked pathogens in clinical medicine, not because it is rare, but because the standard tools used to find it (including both… Continue reading Bartonella: The Blind Spot Pathogen Clinicians Can’t Afford to Miss